ALIPAY+
Whale Cloud , a leading technology company providing software solutions and services for telecommunications and multiple other industries, today reached a partnership with Toka Fintech , a Mexican-leading financial group, to help it develop its own digital payment app with Alipay+ Digital Wallet Solution, providing Mexicans with better access to inclusive financial services.
Toka Fintech is a company belonging to Grupo Toka, which is one of the most important groups in the prepaid card market and has more than 4.5 million customers in Mexico. Grupo Toka is increasingly embracing digital payment services because of the fast adoption of smartphones in the country and the COVID-19 pandemic.
In this partnership, with proven payment technology, project delivery and operation experience from Whale Cloud and Ant Group in global markets, Toka Fintech will further embark on its digital payment journey and bring the inclusive, digitalized and personalized services to more businesses and customers in Mexico.
Whale Cloud and Ant Group will help Toka Fintech develop an all-in-one digital payment app tailored for Latin America market, providing comprehensive payment services powered by innovative technologies including financial-grade cloud native computing and AI-driven risk management.
“As a company that aims to continuously create value for customers, Toka Fintech is taking the lead in encouraging the use of innovative technologies in the delivery of financial services. The partnership with Ant Group and Whale Cloud is a milestone for us to advance financial inclusion,” said Hugo Villanueva, CEO and Owner of Toka Fintech.
“We’re excited to serve the digital payment journey of Toka Fintech,” said Cheng Guoming, General Manager of Alipay+ Global Partnership, Ant Group. “Together with Whale Cloud, we are willing to share our technical know-how and experiences to accelerate customers’ digital transformation and help underbanked communities across the world enjoy more inclusive services.”
“Toka Fintech will be the first in Latin America to adopt Alipay+ Digital Wallet Solution. Whale Cloud is so happy to turn Toka’s strategy into actions to reinforce its market position in advancing inclusive digital services”, said Ben Zhou, CEO International, Whale Cloud.
Alipay+ Digital Wallet Solution provides a full-suite of payment technologies and products to help customers develop their own e-wallet apps more efficiently, enable their users to top up, transfer, withdraw money and enjoy financial services directly from mobile devices, while allow merchants to accept these users' online and offline payments, and manage their own loyalty and promotion campaigns.
Whale Cloud and Ant Group have formed a strategic partnership since 2020 to provide customers across industries with financial technology consulting, solution designing and delivery, and operation services.
About Grupo Toka and Toka Fintech
Toka Internacional, S.A.P.I. de C.V. “Toka” is a Mexican Company active in the issue of payment solutions, through electronic wallets in order to provide food, fuel, restaurant, travel allowance, etc. voucher services. The company started providing call center services to financial institutions and in 2012 they launched their first pre-payment card, business that has grown rapidly and become one of the top 5 electronic wallet issuer companies in Mexico.
In 2019 Toka created “Toka Fintech” as a strategy for continuous growth and taking advantage of the opportunity created by the new Fintech law in Mexico to commercialize its products to a B2C open market.
About Whale Cloud
Whale Cloud Technology Co., Ltd ("Whale Cloud") is a leading technology company specializing in telecom software development and delivery, cloud computing, big data analytics, AI-enabled service operations, IoT, Fintech solutions and other professional services including planning and consulting. Founded in 2003, the company provides services to various market segments including telecom operators, governments, and enterprises around the world. Whale Cloud’s business scope extends from telecom markets to vertical industries. It has built its core competitiveness in communications software, operation services, cloud computing, big data analytics, AI, and Internet architecture.
About Alipay+
Alipay+ provides global cross-border mobile payments and marketing solutions that enable global e-wallets and merchant partners, especially small and medium-sized businesses, to better serve their users and customers.
Alipay+ is introduced by Ant Group, the owner and operator of Alipay. One of the world’s leading digital payment platforms, Alipay serves hundreds of millions of users by connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109006725/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom